enta-8k_20200226.htm
false 0001177648 0001177648 2020-02-26 2020-02-26

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2020

 

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35839

04-3205099

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

500 Arsenal Street,

Watertown, Massachusetts

 

02472

(Address of principal executive offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

ENTA

 

NASDAQ

 


 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the annual meeting of stockholders held on February 26, 2020, Enanta’s stockholders voted on the following proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 17, 2020. 

 

Proposal No. 1: To Elect Two Class I Directors to Serve Until the 2023 Annual Meeting of Stockholders or until their respective successors are elected and qualified. 

The stockholders re-elected the following individuals as Class I directors of the Company:

 

Name of Director Nominee

 

Votes For

 

 

Votes Withheld

 

 

Broker

Non-Votes

 

Bruce L.A. Carter, Ph.D.

 

 

15,986,607

 

 

 

258,954

 

 

 

977,102

 

Jay R. Luly, Ph.D.

 

 

16,194,985

 

 

 

50,576

 

 

 

977,102

 

 

Proposal No. 2: To Approve, on an Advisory Basis, the Compensation Paid to the Company’s Named Executive Officers.

The stockholders approved the advisory vote on executive compensation, or a “say-on-pay” vote.

 

Votes For

 

 

Votes Against

 

 

Abstain

 

 

Broker

Non-Votes

 

 

16,020,567

 

 

 

210,024

 

 

 

14,970

 

 

 

977,102

 

Proposal No. 3: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta’s Independent Registered Public Accounting Firm for the 2020 Fiscal Year. 

The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2020.

Votes For

 

 

Votes Against

 

 

Abstain

 

 

Broker

Non-Votes

 

16,925,959

 

 

 

283,266

 

 

 

13,438

 

 

0

 

 

 

 

 

 

1


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ENANTA PHARMACEUTICALS, INC.

 

 

 

 

Date: March 2, 2020

 

By:

/s/ Paul J. Mellett

 

 

 

Paul J. Mellett

 

 

 

Senior Vice President, Finance and Administration and Chief Financial Officer

 

2

v3.19.3.a.u2
Document and Entity Information
Feb. 26, 2020
Cover [Abstract]  
Entity Registrant Name ENANTA PHARMACEUTICALS, INC.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001177648
Document Period End Date Feb. 26, 2020
Entity Emerging Growth Company false
Entity File Number 001-35839
Entity Incorporation State Country Code DE
Entity Tax Identification Number 04-3205099
Entity Address, Address Line One 500 Arsenal Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 607-0800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ENTA
Security Exchange Name NASDAQ